- Home
- PLRX
as 06-20-2025 4:00pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 84.7M | IPO Year: | 2020 |
| Target Price: | $9.79 | AVG Volume (30 days): | 950.8K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $16.10 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -25.01% |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
GlobeNewswire
a month ago
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Clinical Trials Arena
2 months ago
Pliant cuts workforce by 45% following lung trial termination
MT Newswires
2 months ago
Pliant Therapeutics to lay off 45% of Workforce in Restructuring Move
BioPharma Dive
2 months ago
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma
GlobeNewswire
2 months ago
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
Zacks
2 months ago
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
GlobeNewswire
2 months ago
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.